Early Access — free while we kick the tires
EdgarHawk

Faga Daniel

President, CEO

Director Officer
3 filings analyzed · 1 company · Latest 2026-03-27

Companies

Company Buys Sells Direction
ANAPTYSBIO, INC ANAB 0 15 Net selling

Activity

March 2026
2026-03-27 ANAPTYSBIO, INC ANAB
medium
Sell
17,679 shares
$1,089,199
Significance 6/10

ANAB CEO Faga Daniel sells 17,679 shares (17.7K) for $1,089,198.74 across 10 transactions; stock rose 11%+ in 30 days post-January sales.

Faga Daniel, President and CEO of ANAB, executed 10 separate sales totaling 17,679 shares for $1,089,198.74 on 2026-03-27, reducing his holdings from 513,644 to 495,965 shares (a -3.4% reduction). The sales occurred at prices ranging from $56.61 to $65.99, with a blended average of $61.61, while the current stock price stands at $57.40. Notably, his two most recent prior sales at ANAB on 2026-01-08 and 2026-01-05 both posted strong 30-day returns (+11.2% and +11.8% respectively), suggesting those earlier sales were poorly-timed entries into a rising market. At the same-ticker level, his 90-day well-timed rate is 0 of 2 measurable outcomes, indicating his prior sales at this stock have not preceded declines. The company recently reported revenue of $76,320,000.00 in the latest quarter with net income of $15,113,000.00, but was unprofitable on a full-year basis, and carries a P/E of 34.79 against a market cap of $1,650,149,837.00. The stock is currently -14.7% from its 52-week high of $67.29.

January 2026
2026-01-09 ANAPTYSBIO, INC ANAB
medium
Sell
14,281 shares
$638,504
Significance 4/10

ANAB CEO Faga Daniel sold 14,281 shares at $44.71 on 2026-01-08 (value: $638,503.51); retains 479,344 shares. Stock -12.3% from 52-week high; prior ANAB sales posted +12.0% and +0.5% 90-day returns.

CEO Faga Daniel sold 14,281 shares at $44.71, reducing holdings by 2.9% while retaining a substantial 479,344 share position. This represents a second discretionary sale within 3 days (a prior sale on 2026-01-05 was also reported). The stock has declined 12.3% from its 52-week high of $50.91 but remains positive on a 90-day basis (+42.4%), suggesting recent strength before this transaction. Notably, his two prior measurable sales at ANAB (2024-03-25 and 2024-03-22) were both poorly timed by the 90-day benchmark, with the stock rising +12.0% and +0.5% post-sale; his cross-ticker track record shows a 0.00% well-timed rate across 3 prior sells. The company posted strong recent fundamentals—$76.3M quarterly revenue with +432.0% annual growth and $15.1M net income—though it was unprofitable over its most recent full fiscal year, creating mixed signals about underlying sustainability.

2026-01-06 ANAPTYSBIO, INC ANAB
low
Sell
15,309 shares
$662,267
Significance 4/10

CEO Daniel Faga sold 15,309 shares of ANAB at $43.26 for $662,267.34; holdings now 458,139 shares post-transaction.

Faga, as President and CEO, sold 15,309 shares on 2026-01-05, reducing his holdings by 3.2% to 458,139 shares while retaining substantial position. The sale occurred at $43.26, which was near the stock's 52-week high of $50.91 (within 15% of peak); at current price of $43.91, the executed price was slightly below market. Reviewing his prior trades at ANAB, both prior sells (2024-03-25 and 2024-03-22) were followed by positive 90-day returns (+12.0% and +0.5%), meaning neither sale preceded a decline. His cross-ticker track record shows 0 of 2 prior sells were well-timed, with an average 90-day return of +6.2% after sells. The fundamental backdrop is mixed: company posted revenue of $76,320,000 and net income of $15,113,000 in the latest quarter, alongside annual revenue growth of +432.0%, though it was unprofitable over its most recent full fiscal year. This sale represents a standard diversification move by a substantial shareholder without clear timing differentiation relative to his historical pattern.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access